Lisinopril for IgA nephropathy with focal mesangial proliferation in children

Lisinopril for IgA nephropathy with focal mesangial proliferation in children - Lisinopril for IgA nephropathy with focal mesangial proliferation in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000373

Enrollment

Registered

2006-04-01

Start date

1998-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy in children

Interventions

Lisinopril for 2 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Biopsy diagnoses of IgA nephropathy with focal mesangial proliferation. 2.Proteinuria with a urinary protein-creatinine ratio >0.2. 4.Aged 2 to 18 years. 5.Written informed consent from the patients' parents or legal guardians.

Exclusion criteria

Exclusion criteria: 1.Other renal or systemic forms defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus). 2.Medical history of allergy or hypersensitivity reactions to lisinopuril. 3.Chronic renal dysfunction. 4.Active infectious disease. 5.Severe liver disfunction. 6.History of steroid, immunosupression, ACEI, ARB, Saireito and dipilidamol administration. 7.Pregnancy. 8.Judged inappropriate for this study by the physicians.

Design outcomes

Primary

Measure	Time frame
Disappearance rate of proteinuria	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026